promethazine intramuscularly at a dose of 25 mg (group A)	8 mg betahistine tablets (group B)	Vertigo after intervention	-1	-1	<td align="left" colspan="2" rowspan="1" valign="top">Vertigo after intervention (h)</td><td align="left" colspan="1" rowspan="1" valign="top">1.7 ± 0.59</td><td align="left" colspan="1" rowspan="1" valign="top">1.6 ± 0.39</td><td align="left" colspan="1" rowspan="1" valign="top">NS</td>
8 mg betahistine tablets (group B)	promethazine intramuscularly at a dose of 25 mg (group A)	nausea and vomiting	11884	11923	Nausea and vomiting 3 (3.7%) 11 (13.8%)
8 mg betahistine tablets (group B)	promethazine intramuscularly at a dose of 25 mg (group A)	nausea and vomiting	10630	10692	in group B, nausea and vomiting were observed more frequently,
promethazine intramuscularly at a dose of 25 mg (group A)	8 mg betahistine tablets (group B)	Vertigo after intervention	11251	11306	Vertigo after intervention (h) 1.7 ± 0.59 1.6 ± 0.39 NS
promethazine intramuscularly at a dose of 25 mg (group A)	8 mg betahistine tablets (group B)	drowsiness	11924	11947	Drowsiness 51 (62.2%) 0
promethazine intramuscularly at a dose of 25 mg (group A)	8 mg betahistine tablets (group B)	drowsiness	10776	10950	Unwanted drug side effects were observed only in group A, the most common drowsiness (76.8%) followed by akathisia. But in the group B these adverse effects were not observed
